Chronic inflammatory demyelinating polyneuropathy (CIPD) can have a substantial impact on patients everyday life and, ...

Johnson & Johnson's FcRn inhibitor nipocalimab has been awarded fast-track status by the FDA as a treatment for Sjögren's ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

(Reuters) -Immunovant said on Wednesday its drug for a type of chronic autoimmune disease affecting muscles met the main goal of improving some patients' ability to perform daily activities in a ...

Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.

Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...

Immunovant, Inc. will host an investor webcast on March 19 to discuss Phase 3 study results for batoclimab in MG and CIDP. Immunovant, Inc. announced that it will hold an investor webcast on March ...

The lack of detailed data or outcomes from the Phase 3 study of batoclimab in MG and the Phase 2b study in CIDP prior to the webcast may raise concerns among investors about the effectiveness of ...

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it ...

A blood glucose test measures how much sugar you have in your blood. You may have a blood glucose test in a doctor’s office, laboratory, or with a fingerstick meter at home. When you eat ...